Cancer response to therapy-induced senescence: A matter of dose and timing
Simple Summary Cellular senescence consists of a permanent block of cell proliferation in
the presence of an active metabolism. It is a physiological process occurring when cells …
the presence of an active metabolism. It is a physiological process occurring when cells …
Tyrosine kinase inhibitors and atherosclerosis: a close but complicated relationship
K Xu, H Tang, J Xiong, X Ban, Y Duan, Y Tu - European Journal of …, 2023 - Elsevier
Targeted cancer therapies have revolutionized the treatment of the disease in the past
decade. The tyrosine kinase inhibitor (TKI) class of drugs is a widely used option for treating …
decade. The tyrosine kinase inhibitor (TKI) class of drugs is a widely used option for treating …
Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Senescence is a special state of tumor suppression induced by cell cycle arrest. However,
releasing senescence-associated secretory phenotypes by senescent cells could provide …
releasing senescence-associated secretory phenotypes by senescent cells could provide …
MicroRNA‑21‑5p expression in extracellular vesicles is increased in the blood of aging mice and in vascular endothelial cells induced by ionizing radiation
K Yamamoto, M Chiba - Experimental and Therapeutic …, 2024 - spandidos-publications.com
In recent years, the Japanese population has been aging and the risk of contracting various
age-related diseases has increased. Thus, there is a need to analyze components that are …
age-related diseases has increased. Thus, there is a need to analyze components that are …
Glioblastoma cells do not affect axitinib-dependent senescence of HUVECs in a transwell coculture model
M Merolle, MP Mongiardi, M Piras, A Levi… - International Journal of …, 2020 - mdpi.com
Axitinib is an orally available inhibitor of tyrosine kinases, with high specificity for vascular
endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It is approved for the treatment of …
endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It is approved for the treatment of …
L-茶氨酸抑制P53/P16 改善D-半乳糖诱导的人脐静脉内皮细胞和心肌细胞损伤
刘敏, 刘晓峰, 张苏川, 姚峰, 王莉, 朱磊, 程波… - 临床心血管病 …, 2020 - whuhzzs.com
目的: 探讨L-茶氨酸对D-半乳糖诱导人脐静脉内皮细胞(HUVECs) 和心肌细胞(H9c2)
损伤的保护作用. 方法: 通过D-半乳糖诱导HUVECs 和H9c2 细胞损伤. 采用CCK8 …
损伤的保护作用. 方法: 通过D-半乳糖诱导HUVECs 和H9c2 细胞损伤. 采用CCK8 …
[PDF][PDF] Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing. Cancers 2021, 13, 484
Cellular senescence participates to fundamental processes like tissue remodeling in embryo
development, wound healing and inhibition of preneoplastic cell growth. Most senescent …
development, wound healing and inhibition of preneoplastic cell growth. Most senescent …
L-theanine protects against D-galactose-induced injury of human umbilical vein endothelial cells and cardiomyocytes via inhibiting P53/P16
LIU Min, LIU Xiaofeng, Z Suchuan, YAO Feng… - J Clin …, 2020 - lcxxgen.whuhzzs.com
Objective: To investigate the protective effects of L-theanine against D-galactose-induced
injury of human umbilical vein endothelial cells (HUVECs) and cardiomyocytes (H9c2) …
injury of human umbilical vein endothelial cells (HUVECs) and cardiomyocytes (H9c2) …